Sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) are antibody-drug conjugates (ADCs) approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (MBC).
Both carry topoisomerase-1-inhibiting payloads, and it is unknown whether these drugs retain activity when used sequentially.
